Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. Hayashi RJ, et al. Among authors: harker murray p. Blood. 2024 May 16;143(20):2053-2058. doi: 10.1182/blood.2023021184. Blood. 2024. PMID: 38457359 Clinical Trial.
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Teachey DT, et al. Among authors: harker murray p. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10. J Clin Oncol. 2022. PMID: 35271306 Free PMC article. Clinical Trial.
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Castellino SM, et al. Among authors: harker murray p. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. Pediatr Blood Cancer. 2023. PMID: 37505794
Editorial: Non-cellular immunotherapies in pediatric malignancies.
Alexander S, Harker-Murray P, Hayashi RJ. Alexander S, et al. Among authors: harker murray p. Front Immunol. 2024 Feb 21;15:1379278. doi: 10.3389/fimmu.2024.1379278. eCollection 2024. Front Immunol. 2024. PMID: 38449864 Free PMC article. No abstract available.
Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group.
Esbenshade AJ, Pierson CR, Thompson AL, Reed D, Gupta A, Levy A, Kahalley LS, Harker-Murray P, Schore R, Muscal JA, Embry L, Maloney K, Horton T, Zweidler-Mckay P, Dhall G. Esbenshade AJ, et al. Pediatr Blood Cancer. 2018 Mar;65(3):10.1002/pbc.26878. doi: 10.1002/pbc.26878. Epub 2017 Nov 28. Pediatr Blood Cancer. 2018. PMID: 29193588 Free PMC article.
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Harker-Murray P, et al. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. Blood. 2023. PMID: 36564047 Free PMC article. Clinical Trial.
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, Deyell RJ, Flerlage JE, Franklin AK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen F, Yan AP, Harker-Murray PD, Giulino-Roth L. Forlenza CJ, et al. Among authors: harker murray pd. Blood Adv. 2023 Jul 11;7(13):3225-3231. doi: 10.1182/bloodadvances.2022009323. Blood Adv. 2023. PMID: 36897253 Free PMC article.
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. Goldman S, et al. Leukemia. 2021 Oct;35(10):2994-2997. doi: 10.1038/s41375-021-01256-8. Epub 2021 May 3. Leukemia. 2021. PMID: 33941850 No abstract available.
27 results